Avara Pharmaceutical to buy Novartis’s production plant in Canada

US-based Avara Pharmaceutical Services has signed an asset purchase agreement to acquire Novartis Technical Operations’ sterile manufacturing facility for injectable medicines in Quebec, Canada.

The deal also covers the nearby Sandoz Development Center situated on the Sandoz Canada campus in Boucherville.

Said to be the biggest injectables production facility in Canada, the site supplies multiple drugs across the country’s healthcare system, primarily hospitals.

Avara is planning to invest in the facility and work on business development opportunities in order to optimise the site’s utilisation and boost its customer base.

The company noted that employees may not be impacted by the move.

Avara Pharmaceutical Services chairman and CEO Timothy Tyson said: "This acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand.

"This further expands our sterile processing capability, which is in very high demand."

"It comes with a world-class development centre and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements."

Register as Visitor to CPhI China 2018!